Aardvark Therapeutics

Rare‑disease drugs often command high prices, and competitor Vykat XR reportedly launched around 466 thousand dollars per year, indicating payer tolerance for premium pricing in PWS if value is clear.

As a second entrant, ARD‑101’s pricing power would depend on demonstrable benefits versus Vykat XR on hyperphagia control, adverse events and caregiver burden. Given paused development and no head‑to‑head or long‑term data, latent pricing power is currently theoretical rather than evidenced.